Application of a methylation gene panel by quantitative PCR for lung cancers

Narayan Shivapurkar, Victor Stastny, Makoto Suzuki, Ignacio I. Wistuba, Lin Li, Yingye Zheng, Ziding Feng, Bernard Hol, Clemens Prinsen, Frederik B. Thunnissen, Adi F. Gazdar

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Detection of lung cancer at early stages could potentially increase survival rates. One promising approach is the application of suitable lung cancer-specific biomarkers to specimens obtained by non-invasive methods. Thus far, clinically useful biomarkers that have high sensitivity have proven elusive. Certain genes, which are involved in cellular pathways such as signal transduction, apoptosis, cell to cell communication, cell cycles and cytokine signaling are down-regulated in cancers and may be considered as potential tumor suppressor genes. Aberrant promoter hypermethylation is a major mechanism for silencing tumor suppressor genes in many kinds of human cancers. Using quantitative real time PCR, we tested 11 genes (3-OST-2, RASSF1A, DcR1, DcR2, P16, DAPK, APC, ECAD, HCAD, SOCS1, SOCS3) for levels of methylation within their promoter sequences in non-small cell lung cancers (NSCLC), adjacent non-malignant lung tissues, in peripheral blood mononuclear cells (PBMC) from cancer free patients, in sputum of cancer patients and controls. Of all the 11 genes tested 3-OST-2 showed the highest levels of promoter methylation in tumors combined with lowest levels of promoter methylation in control tissues. 3-OST-2 followed by, RASSF1A showed increased levels of methylation with advanced tumor stage (P<0.05). Thus, quantitative analysis of 3-OST-2 and RASSF1A methylation appears to be a promising biomarker assay for NSCLC and should be further explored in a clinical study. Our preliminary data on the analysis of sputum DNA specimens from cancer patients further support these observations.

Original languageEnglish (US)
Pages (from-to)56-71
Number of pages16
JournalCancer Letters
Volume247
Issue number1-2
DOIs
StatePublished - Mar 8 2007

Fingerprint

Methylation
Lung Neoplasms
Polymerase Chain Reaction
Genes
Neoplasms
Tumor Suppressor Genes
Sputum
Non-Small Cell Lung Carcinoma
Biomarkers
Tumor Biomarkers
Cell Communication
Real-Time Polymerase Chain Reaction
Signal Transduction
Blood Cells
Cell Cycle
Survival Rate
Apoptosis
Cytokines
Lung
DNA

Keywords

  • Non-small cell lung cancer
  • Real time PCR
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Shivapurkar, N., Stastny, V., Suzuki, M., Wistuba, I. I., Li, L., Zheng, Y., ... Gazdar, A. F. (2007). Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Letters, 247(1-2), 56-71. https://doi.org/10.1016/j.canlet.2006.03.020

Application of a methylation gene panel by quantitative PCR for lung cancers. / Shivapurkar, Narayan; Stastny, Victor; Suzuki, Makoto; Wistuba, Ignacio I.; Li, Lin; Zheng, Yingye; Feng, Ziding; Hol, Bernard; Prinsen, Clemens; Thunnissen, Frederik B.; Gazdar, Adi F.

In: Cancer Letters, Vol. 247, No. 1-2, 08.03.2007, p. 56-71.

Research output: Contribution to journalArticle

Shivapurkar, N, Stastny, V, Suzuki, M, Wistuba, II, Li, L, Zheng, Y, Feng, Z, Hol, B, Prinsen, C, Thunnissen, FB & Gazdar, AF 2007, 'Application of a methylation gene panel by quantitative PCR for lung cancers', Cancer Letters, vol. 247, no. 1-2, pp. 56-71. https://doi.org/10.1016/j.canlet.2006.03.020
Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y et al. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Letters. 2007 Mar 8;247(1-2):56-71. https://doi.org/10.1016/j.canlet.2006.03.020
Shivapurkar, Narayan ; Stastny, Victor ; Suzuki, Makoto ; Wistuba, Ignacio I. ; Li, Lin ; Zheng, Yingye ; Feng, Ziding ; Hol, Bernard ; Prinsen, Clemens ; Thunnissen, Frederik B. ; Gazdar, Adi F. / Application of a methylation gene panel by quantitative PCR for lung cancers. In: Cancer Letters. 2007 ; Vol. 247, No. 1-2. pp. 56-71.
@article{807171f9ac644b0882f52d0135d57e1b,
title = "Application of a methylation gene panel by quantitative PCR for lung cancers",
abstract = "Detection of lung cancer at early stages could potentially increase survival rates. One promising approach is the application of suitable lung cancer-specific biomarkers to specimens obtained by non-invasive methods. Thus far, clinically useful biomarkers that have high sensitivity have proven elusive. Certain genes, which are involved in cellular pathways such as signal transduction, apoptosis, cell to cell communication, cell cycles and cytokine signaling are down-regulated in cancers and may be considered as potential tumor suppressor genes. Aberrant promoter hypermethylation is a major mechanism for silencing tumor suppressor genes in many kinds of human cancers. Using quantitative real time PCR, we tested 11 genes (3-OST-2, RASSF1A, DcR1, DcR2, P16, DAPK, APC, ECAD, HCAD, SOCS1, SOCS3) for levels of methylation within their promoter sequences in non-small cell lung cancers (NSCLC), adjacent non-malignant lung tissues, in peripheral blood mononuclear cells (PBMC) from cancer free patients, in sputum of cancer patients and controls. Of all the 11 genes tested 3-OST-2 showed the highest levels of promoter methylation in tumors combined with lowest levels of promoter methylation in control tissues. 3-OST-2 followed by, RASSF1A showed increased levels of methylation with advanced tumor stage (P<0.05). Thus, quantitative analysis of 3-OST-2 and RASSF1A methylation appears to be a promising biomarker assay for NSCLC and should be further explored in a clinical study. Our preliminary data on the analysis of sputum DNA specimens from cancer patients further support these observations.",
keywords = "Non-small cell lung cancer, Real time PCR, Tumor suppressor gene",
author = "Narayan Shivapurkar and Victor Stastny and Makoto Suzuki and Wistuba, {Ignacio I.} and Lin Li and Yingye Zheng and Ziding Feng and Bernard Hol and Clemens Prinsen and Thunnissen, {Frederik B.} and Gazdar, {Adi F.}",
year = "2007",
month = "3",
day = "8",
doi = "10.1016/j.canlet.2006.03.020",
language = "English (US)",
volume = "247",
pages = "56--71",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Application of a methylation gene panel by quantitative PCR for lung cancers

AU - Shivapurkar, Narayan

AU - Stastny, Victor

AU - Suzuki, Makoto

AU - Wistuba, Ignacio I.

AU - Li, Lin

AU - Zheng, Yingye

AU - Feng, Ziding

AU - Hol, Bernard

AU - Prinsen, Clemens

AU - Thunnissen, Frederik B.

AU - Gazdar, Adi F.

PY - 2007/3/8

Y1 - 2007/3/8

N2 - Detection of lung cancer at early stages could potentially increase survival rates. One promising approach is the application of suitable lung cancer-specific biomarkers to specimens obtained by non-invasive methods. Thus far, clinically useful biomarkers that have high sensitivity have proven elusive. Certain genes, which are involved in cellular pathways such as signal transduction, apoptosis, cell to cell communication, cell cycles and cytokine signaling are down-regulated in cancers and may be considered as potential tumor suppressor genes. Aberrant promoter hypermethylation is a major mechanism for silencing tumor suppressor genes in many kinds of human cancers. Using quantitative real time PCR, we tested 11 genes (3-OST-2, RASSF1A, DcR1, DcR2, P16, DAPK, APC, ECAD, HCAD, SOCS1, SOCS3) for levels of methylation within their promoter sequences in non-small cell lung cancers (NSCLC), adjacent non-malignant lung tissues, in peripheral blood mononuclear cells (PBMC) from cancer free patients, in sputum of cancer patients and controls. Of all the 11 genes tested 3-OST-2 showed the highest levels of promoter methylation in tumors combined with lowest levels of promoter methylation in control tissues. 3-OST-2 followed by, RASSF1A showed increased levels of methylation with advanced tumor stage (P<0.05). Thus, quantitative analysis of 3-OST-2 and RASSF1A methylation appears to be a promising biomarker assay for NSCLC and should be further explored in a clinical study. Our preliminary data on the analysis of sputum DNA specimens from cancer patients further support these observations.

AB - Detection of lung cancer at early stages could potentially increase survival rates. One promising approach is the application of suitable lung cancer-specific biomarkers to specimens obtained by non-invasive methods. Thus far, clinically useful biomarkers that have high sensitivity have proven elusive. Certain genes, which are involved in cellular pathways such as signal transduction, apoptosis, cell to cell communication, cell cycles and cytokine signaling are down-regulated in cancers and may be considered as potential tumor suppressor genes. Aberrant promoter hypermethylation is a major mechanism for silencing tumor suppressor genes in many kinds of human cancers. Using quantitative real time PCR, we tested 11 genes (3-OST-2, RASSF1A, DcR1, DcR2, P16, DAPK, APC, ECAD, HCAD, SOCS1, SOCS3) for levels of methylation within their promoter sequences in non-small cell lung cancers (NSCLC), adjacent non-malignant lung tissues, in peripheral blood mononuclear cells (PBMC) from cancer free patients, in sputum of cancer patients and controls. Of all the 11 genes tested 3-OST-2 showed the highest levels of promoter methylation in tumors combined with lowest levels of promoter methylation in control tissues. 3-OST-2 followed by, RASSF1A showed increased levels of methylation with advanced tumor stage (P<0.05). Thus, quantitative analysis of 3-OST-2 and RASSF1A methylation appears to be a promising biomarker assay for NSCLC and should be further explored in a clinical study. Our preliminary data on the analysis of sputum DNA specimens from cancer patients further support these observations.

KW - Non-small cell lung cancer

KW - Real time PCR

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=33845662751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845662751&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2006.03.020

DO - 10.1016/j.canlet.2006.03.020

M3 - Article

VL - 247

SP - 56

EP - 71

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1-2

ER -